National Bank of Canada
NAMS icon

National Bank of Canada’s NewAmsterdam Pharma NAMS Stock Holding History

National Bank of Canada’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.4K Sell
1,813
-204
-10% -$6.72K ﹤0.01% 1975
2026
Q1 		$64.5K Hold
2,017
– – ﹤0.01% 1895
2025
Q4 		$70.8K Buy
2,017
+68
+3% +$2.48K ﹤0.01% 1877
2025
Q3 		$55.3K Sell
1,949
-32
-2% -$767 ﹤0.01% 1909
2025
Q2 		$35.9K Buy
1,981
+149
+8% +$2.72K ﹤0.01% 2034
2025
Q1 		$37.5K Sell
1,832
-168
-8% -$3.73K ﹤0.01% 1944
2024
Q4 		$51.4K Buy
+2,000
New +$42.5K ﹤0.01% 1942

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

National Bank of Canada's NAMS Position: Q2 2026 in Review

National Bank of Canada reduced its NewAmsterdam Pharma (NAMS) stake by 10% in Q2 2026, selling an estimated $6.72K and leaving 1,813 shares worth $61.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1975.

National Bank of Canada first reported a position in NAMS in Q4 2024 and has held it in 7 quarters since. The position peaked at $70.8K in Q4 2025. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • National Bank of Canada held 1,813 shares of NewAmsterdam Pharma worth $61.4K as of Q2 2026.
  • National Bank of Canada sold 204 NewAmsterdam Pharma shares in Q2 2026, an estimated $6.72K.
  • NewAmsterdam Pharma made up ﹤0.01% of National Bank of Canada's portfolio in Q2 2026, its #1975 holding.
  • National Bank of Canada first reported a position in NewAmsterdam Pharma in Q4 2024 and has held it in 7 quarters since.
  • National Bank of Canada's NewAmsterdam Pharma position peaked at $70.8K in Q4 2025.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.